# Combination of Gonadotropin-releasing Hormone Agonist and Human Chorionic Gonadotropin Triggered by Normal Responder in GnRH-antagonist Cycles

> **NCT02862782** · PHASE3 · UNKNOWN · sponsor: **Tel-Aviv Sourasky Medical Center** · enrollment: 1000 (estimated)

## Conditions studied

- In-vitro Fertilization

## Interventions

- **DRUG:** hCG (Ovitrelle 250 mcg mcg - Merck Serono)
- **DRUG:** hCG (Ovitrelle 250 mcg mcg - Merck Serono) + GnRH agonist (Decapeptyl 0.2mg - Ferring Gmgh)

## Key facts

- **NCT ID:** NCT02862782
- **Lead sponsor:** Tel-Aviv Sourasky Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-09
- **Primary completion:** 2019-09
- **Final completion:** 2019-09
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2016-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02862782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02862782, "Combination of Gonadotropin-releasing Hormone Agonist and Human Chorionic Gonadotropin Triggered by Normal Responder in GnRH-antagonist Cycles". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02862782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*